Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation
Main finding · Incident goutResult — go to the resultHazard ratio 0.80 95% CI 0.76–0.84Authors' conclusion
SGLT2i therapy is associated with a lower risk of incident gout compared to DPP4i in patients with type 2 diabetes.
Study context
- Population
- Patients with T2D, Korean National Health Insurance Service database (2015–2020)20,866 matched pairs
- Exposure
- SGLT2i vs DPP4i
- Outcome
- Incident gout
Methodological detailsnew-user active comparator, 1:1 propensity score matched, two-sample Mendelian randomisation (MR)
- New-user active comparator
- 1:1 propensity score matched
- Two-sample MR
Main finding
As reported in the abstract
Hazard ratio
0.80
95% CI 0.76–0.84
P < 0.001
By group
SGLT2i
2792.6 per 100 000 person-years
DPP4i
3346.7 per 100 000 person-years
SGLT2ivs DPP4i
HR 0.80 (95% CI 0.76–0.84); P < 0.001
Observational data: associations, not effects.
Further findings
Gout risk with genetically proxied SGLT2 inhibition (MR, SLC5A2 variants; FinnGen)
| OR per 1-SD decrease in HbA1c (95% CI) | P value | ||
|---|---|---|---|
| Genetically proxied SGLT2 inhibition | 0.10 (0.017–0.463) | P < 0.001 | |
| 0.050.21520Odds ratio per 1-SD decrease in HbA1c (log scale) |
- Consistent results across robust MR methods
Original publication
Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation. Diabetes Obes Metab. Published 21 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →